Low-Dose Cyclobenzaprine for Depression Treatment

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for treating depression often come with significant side effects and there is a need for new approaches that can effectively address depression with minimal adverse effects.

Innovation Solution

A pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine, either alone or in combination with an antidepressant drug, administered at a low dose to treat depression, including major depressive disorder, with the option to adjust dosage and administration route to minimize side effects and enhance efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antidepressant drugs are used to treat depression, then depression symptoms are effectively treated, but significant side effects occur

Engineering Contradiction:
Improvedepression treatment efficacyVSAvoidside effects
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the dosage parameter by using very low doses of cyclobenzaprine (less than 5 mg/day) compared to conventional antidepressant dosing, thereby achieving depression treatment with minimal side effects. This parameter change transforms the drug from a high-dose conventional antidepressant to a low-dose formulation that maintains efficacy while reducing harmful effects.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs cyclobenzaprine, a short-acting muscle relaxant, as a temporary and inexpensive alternative to conventional antidepressants. The drug is administered at very low doses for limited periods to achieve depression remission without the long-term side effect profile of conventional antidepressants, effectively using a short-acting agent to solve a long-term problem.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

2Reliability

If higher doses of cyclobenzaprine are used, then depression symptoms improve, but side effects increase

Engineering Contradiction:
Improvedepression symptom improvementVSAvoidside effects
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial action by using very low doses of cyclobenzaprine (less than 5 mg/day) that are insufficient for conventional muscle relaxant effects but sufficient for depression treatment. This partial dosing strategy achieves the desired therapeutic effect (depression improvement) while avoiding excessive action that would cause harmful side effects.

Inventive Principle:
Principle #16Partial or excessive action

Data Source

PatentUS11998516B2Methods and compositions for treating depression using cyclobenzaprine
Publication Date: 2024.06.04 TONIX PHARMA LTD

AI summary

The present invention relates to methods for the treatment or prevention of depression, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising cyclobenzaprine, alone, or in combination with an antidepressant drug.